AstraZeneca has signed a multi-year agreement with artificial intelligence biotechnology company insitro to discover and develop treatments for serious liver and heart conditions, with an upfront payment of $40 million and potential development and commercial milestone payments of approximately $1.46 billion (15/10).

The agreement also provides insitro with royalties amounting to a single-digit percentage of future sales.

AstraZeneca and Insitro Target Liver and Heart Diseases

The collaboration will focus on metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease, and cardiomyopathies, a group of diseases that affect the heart muscle. According to AstraZeneca, both conditions have historically lacked effective treatments because researchers have struggled to identify their underlying biological causes.

Under the agreement, insitro will use its artificial intelligence technology to identify the biological processes that cause these diseases. The company will also advance drug targets selected by AstraZeneca from the discovery stage to the development-candidate stage.

Insitro Uses AI to Identify Potential Drug Targets

Insitro will use its Virtual Human platform, which combines laboratory-grown cell models and machine learning, to support the research. The platform will help identify disease biology and advance the targets selected by AstraZeneca.

Sharon Barr, executive vice president of biopharmaceuticals research and development at AstraZeneca, told Reuters that selecting new targets for drug discovery remains one of the most difficult parts of the company's research and development work.

"Choosing the new targets that we want to put into our discovery pipeline is one of the hardest things we do across research and development," Barr said.

She explained that researchers can lose the opportunity to pursue new discoveries early because information about biological pathways and targets may already be publicly available by the time it appears in major scientific journals.

"By the time we read about a new pathway or target (in major scientific journals), it is no longer novel. It's in the public domain and we're already a few steps too late. But when we identify these unique connections early and test them in cellular systems, we're ahead of the game."

Barr added that combining AI tools with experienced scientists allows AstraZeneca to test fewer molecules in the laboratory, reduce guesswork, and accelerate the search for effective medicines.

AstraZeneca to Fund Future Clinical Trials

Under the multi-year agreement, AstraZeneca will be responsible for conducting and funding future clinical trials after insitro advances the selected targets to the development-candidate stage.

Insitro will receive an upfront payment of $40 million and could earn up to approximately $1.46 billion in development and commercial milestone payments. The biotechnology company will also be eligible for royalties representing a single-digit percentage of future sales.

Insitro Expands Pharmaceutical Industry Partnerships

The agreement with AstraZeneca follows insitro's other collaborations with pharmaceutical companies. The biotechnology company recently expanded its partnership with Bristol Myers Squibb to advance a broader portfolio of targets for amyotrophic lateral sclerosis (ALS).

Insitro has also partnered with Eli Lilly to develop AI models that predict the pharmacological properties of small molecules in living organisms.

PHOTO: ANTARA/XINHUA

This article was created with AI assistance.

We make every effort to ensure the accuracy of our content, some information may be incorrect or outdated. Please let us know of any corrections at [email protected].